He warned that obesity is driving a surge in serious illnesses, including Type 2 diabetes and heart disease, placing growing pressure on families, communities and the health system.

Clinical and payer strategies should treat GLP‑1 therapy as chronic for high-risk patients, addressing tolerability and cost ...

People who quit taking popular GLP-1 drugs such as Ozempic might their jeopardize heart health, according to a new study.

Research finds that even short gaps in treatment with a GLP-1 can drive up risks of heart attack, stroke and death in patients with Type 2 diabetes.

Drug executives say only their GLP-1 drugs are safe for treating obesity and diabetes as they wage a yearlong campaign to stop independent labs from producing cheaper versions.

It's 'definitely not a measure of fatness,' and it doesn't accurately define what it means to be overweight. Body mass index isn't always the best predictor of health. In the age of weight-loss drugs, ...

Two related studies published recently by international teams—including researchers with the UCLA Fielding School of Public ...

Epigenetic programming from prolonged undernutrition and terror can persist 3–4 generations, plausibly contributing to elevated cardiometabolic and mental health burdens documented among Irish cohorts ...

Nearly 1 in 5 teens in the United States is obese, putting their long-term health at serious risk. Obesity in adolescence ...

While overall life expectancy in the US has improved slightly in the last couple of years, that could change as these ...

A popular class of drugs for treating diabetes and obesity reduces addiction, including abuse of alcohol, tobacco, cannabis, ...